PRIVIA HEALTH GROUP INC (PRVA) Stock Fundamental Analysis
NASDAQ:PRVA - Nasdaq - US74276R1023 - Common Stock - Currency: USD
Taking everything into account, PRVA scores 4 out of 10 in our fundamental rating. PRVA was compared to 103 industry peers in the Health Care Providers & Services industry. PRVA has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, PRVA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PRVA had positive earnings in the past year.
PRVA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PRVA reported negative net income in multiple years.
Each year in the past 5 years PRVA had a positive operating cash flow.
1.2 Ratios
PRVA has a Return On Assets (1.32%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of 2.37%, PRVA is in line with its industry, outperforming 54.37% of the companies in the same industry.
With a Return On Invested Capital value of 2.00%, PRVA perfoms like the industry average, outperforming 44.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.32% | ||
| ROE | 2.37% | ||
| ROIC | 2% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRVA has a Profit Margin (0.87%) which is comparable to the rest of the industry.
PRVA's Profit Margin has declined in the last couple of years.
PRVA's Operating Margin of 1.19% is in line compared to the rest of the industry. PRVA outperforms 45.63% of its industry peers.
In the last couple of years the Operating Margin of PRVA has declined.
PRVA has a worse Gross Margin (10.09%) than 75.73% of its industry peers.
In the last couple of years the Gross Margin of PRVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.19% | ||
| PM (TTM) | 0.87% | ||
| GM | 10.09% |
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PRVA is destroying value.
The number of shares outstanding for PRVA has been increased compared to 1 year ago.
PRVA has more shares outstanding than it did 5 years ago.
PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.52 indicates that PRVA is not in any danger for bankruptcy at the moment.
PRVA has a Altman-Z score of 4.52. This is in the better half of the industry: PRVA outperforms 78.64% of its industry peers.
PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.52 |
ROIC/WACC0.23
WACC8.87%
2.3 Liquidity
A Current Ratio of 1.88 indicates that PRVA should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.88, PRVA is in the better half of the industry, outperforming 68.93% of the companies in the same industry.
A Quick Ratio of 1.88 indicates that PRVA should not have too much problems paying its short term obligations.
The Quick ratio of PRVA (1.88) is better than 72.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 |
3. Growth
3.1 Past
The earnings per share for PRVA have decreased strongly by -20.00% in the last year.
The Earnings Per Share has been growing slightly by 7.43% on average over the past years.
PRVA shows a small growth in Revenue. In the last year, the Revenue has grown by 6.79%.
Measured over the past years, PRVA shows a quite strong growth in Revenue. The Revenue has been growing by 17.17% on average per year.
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%50%
Revenue 1Y (TTM)6.79%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%12.84%
3.2 Future
Based on estimates for the next years, PRVA will show a very strong growth in Earnings Per Share. The EPS will grow by 62.51% on average per year.
PRVA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.21% yearly.
EPS Next Y90.75%
EPS Next 2Y76.06%
EPS Next 3Y62.51%
EPS Next 5YN/A
Revenue Next Year11.76%
Revenue Next 2Y11.14%
Revenue Next 3Y11.67%
Revenue Next 5Y0.21%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 157.17 indicates a quite expensive valuation of PRVA.
Compared to the rest of the industry, the Price/Earnings ratio of PRVA is on the same level as its industry peers.
PRVA is valuated expensively when we compare the Price/Earnings ratio to 26.82, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 55.31, PRVA can be considered very expensive at the moment.
PRVA's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 36.21. PRVA is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 157.17 | ||
| Fwd PE | 55.31 |
4.2 Price Multiples
61.16% of the companies in the same industry are cheaper than PRVA, based on the Enterprise Value to EBITDA ratio.
PRVA's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.43 | ||
| EV/EBITDA | 66.51 |
4.3 Compensation for Growth
PRVA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as PRVA's earnings are expected to grow with 62.51% in the coming years.
PEG (NY)1.73
PEG (5Y)21.14
EPS Next 2Y76.06%
EPS Next 3Y62.51%
5. Dividend
5.1 Amount
PRVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
18.86
-0.66 (-3.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.99%
Inst Owner Change-0.12%
Ins Owners1.86%
Ins Owner Change1.07%
Market Cap2.30B
Analysts84.29
Price Target31.21 (65.48%)
Short Float %2.74%
Short Ratio3.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.31%
Min EPS beat(2)-40.79%
Max EPS beat(2)-37.83%
EPS beat(4)0
Avg EPS beat(4)-38.4%
Min EPS beat(4)-40.79%
Max EPS beat(4)-36.27%
EPS beat(8)1
Avg EPS beat(8)-32.84%
EPS beat(12)5
Avg EPS beat(12)107.25%
EPS beat(16)8
Avg EPS beat(16)62.22%
Revenue beat(2)2
Avg Revenue beat(2)4.34%
Min Revenue beat(2)0.75%
Max Revenue beat(2)7.92%
Revenue beat(4)4
Avg Revenue beat(4)2.8%
Min Revenue beat(4)0.75%
Max Revenue beat(4)7.92%
Revenue beat(8)8
Avg Revenue beat(8)2.56%
Revenue beat(12)8
Avg Revenue beat(12)-7.79%
Revenue beat(16)10
Avg Revenue beat(16)-10%
PT rev (1m)0%
PT rev (3m)3.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.83%
Revenue NQ rev (1m)-0.16%
Revenue NQ rev (3m)0.92%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)0.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 157.17 | ||
| Fwd PE | 55.31 | ||
| P/S | 1.28 | ||
| P/FCF | 19.43 | ||
| P/OCF | 19.43 | ||
| P/B | 3.49 | ||
| P/tB | 5.61 | ||
| EV/EBITDA | 66.51 |
EPS(TTM)0.12
EY0.64%
EPS(NY)0.34
Fwd EY1.81%
FCF(TTM)0.97
FCFY5.15%
OCF(TTM)0.97
OCFY5.15%
SpS14.77
BVpS5.41
TBVpS3.36
PEG (NY)1.73
PEG (5Y)21.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.32% | ||
| ROE | 2.37% | ||
| ROCE | 3% | ||
| ROIC | 2% | ||
| ROICexc | 5.87% | ||
| ROICexgc | N/A | ||
| OM | 1.19% | ||
| PM (TTM) | 0.87% | ||
| GM | 10.09% | ||
| FCFM | 6.57% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-10.22%
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
F-Score6
Asset Turnover1.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 111.34 | ||
| Cash Conversion | 412.04% | ||
| Profit Quality | 757.69% | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 | ||
| Altman-Z | 4.52 |
F-Score6
WACC8.87%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%50%
EPS Next Y90.75%
EPS Next 2Y76.06%
EPS Next 3Y62.51%
EPS Next 5YN/A
Revenue 1Y (TTM)6.79%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%12.84%
Revenue Next Year11.76%
Revenue Next 2Y11.14%
Revenue Next 3Y11.67%
Revenue Next 5Y0.21%
EBIT growth 1Y45%
EBIT growth 3YN/A
EBIT growth 5Y1.07%
EBIT Next Year515.6%
EBIT Next 3Y106.09%
EBIT Next 5Y64.58%
FCF growth 1Y202.94%
FCF growth 3Y26.09%
FCF growth 5Y42.42%
OCF growth 1Y202.4%
OCF growth 3Y25.67%
OCF growth 5Y35.01%